Galectin Therapeutics Inc (GALT) Stock Analysis
Verdict: HOLD
FDA Phase 3 alignment provides a regulatory floor, but a $17M cash pile against a $24M burn makes a dilutive capital raise likely by Q4.
Investment score: 62/100
Analysis as of
Is Galectin Therapeutics Inc stock worth reviewing? AI model thesis
GALT is a high-conviction binary play on MASH cirrhosis with recent positive regulatory momentum.
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 30/100 (weight 15%)
- Technical Momentum: 85/100 (weight 15%)
- Earnings Quality: 50/100 (weight 15%)
- Insider Sentiment: 75/100 (weight 10%)
- Analyst Consensus: 80/100 (weight 10%)
- Risk-Adjusted Return: 55/100 (weight 15%)
Galectin Therapeutics Inc opportunities and risks
What speaks for GALT
- FDA Type C Meeting Alignment
What speaks against GALT
- Imminent Dilution Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| GALT | n/a | 0.0x | n/a | 0.0% | 0.0% | -7.8% |
| IVVD | n/a | 4.9x | n/a | 92.0% | -138.9% | -28.9% |
| ARMP | n/a | 91.2x | n/a | 72.2% | -9554.2% | -9.1% |
| OTLK | n/a | 207.5x | n/a | -360.9% | -18297.5% | -68.1% |
| TLSI | n/a | 3.5x | n/a | 85.1% | -60.9% | -12.9% |
| ZNTL | n/a | 0.0x | n/a | 0.0% | 0.0% | -44.4% |
| Peer median | n/a | 4.9x | n/a | 72.2% | -138.9% | -28.9% |
Frequently asked questions about Galectin Therapeutics Inc (GALT)
Is GALT stock a good investment?
The cached TradeMates AI model rates Galectin Therapeutics Inc as HOLD with an investment score of 62/100. GALT is a high-conviction binary play on MASH cirrhosis with recent positive regulatory momentum. This is algorithmic model output, not personal investment advice.
Is GALT stock a buy?
The TradeMates model verdict for GALT is HOLD with an investment score of 62/100. Treat this as a model signal to review, not a personal buy recommendation.